InterveXion Announces Expansion of Executive Leadership Team

Little Rock, AR (13 May 2019) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, today announced an expansion to its Executive Leadership Team that strengthens the team...

Meth on the rise in New Jersey

In August 2018, the DEA Intelligence Program, in conjunction with the NY/NJ High Intensity Drug Trafficking Area program and the NJ State Police Regional Operations Intelligence Center’s Drug Monitoring Initiative assessed the methamphetamine drug threat in New...